Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2000-5-4
pubmed:abstractText
The possible mechanisms underlying the vasodilatation induced by olprinone, a phosphodiesterase type III inhibitor, were investigated in smooth muscle of the rabbit coronary artery. Isometric force and membrane potential were measured simultaneously using endothelium-denuded smooth muscle strips. Acetylcholine (ACh, 3 microM) produced a contraction with a membrane depolarization (15. 2+/-1.1 mV). In a solution containing 5.9 mM K(+), olprinone (100 microM) hyperpolarized the resting membrane and (i) caused the absolute membrane potential level reached with ACh to be more negative (but did not reduce the delta membrane potential seen with ACh, 15.2+/-1.8 mV) and (ii) attenuated the ACh-induced contraction. In a solution containing 30 mM K(+), these effects were not seen with olprinone. Glibenclamide (10 microM) blocked the olprinone-induced membrane hyperpolarization. 4-AP (0.1 mM) significantly attenuated the olprinone-induced resting membrane hyperpolarization but TEA (1 mM) had no such effect. Glibenclamide (10 +microM), TEA (1 mM) and 4-AP (0.1 mM), given separately, all failed to modify the inhibitory actions of olprinone on (i) the absolute membrane potential level seen with ACh and (ii) the ACh-induced contraction. It is suggested that olprinone inhibits the ACh-induced contraction through an effect on the absolute level of membrane potential achieved with ACh in smooth muscle of the rabbit coronary artery. It is also suggested that glibenclamide-sensitive, ATP-sensitive K(+) channels do not play an important role in the olprinone-induced inhibition of the ACh-induced contraction.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-1667330, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-2172582, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-2566308, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-2719742, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-7529310, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-7582479, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-7611497, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-7733230, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-7736650, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-7824045, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-8298800, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-8335835, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-8405122, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-8503914, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-8853330, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-9087587, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-9118527, http://linkedlifedata.com/resource/pubmed/commentcorrection/10696101-9495275
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/3',5'-Cyclic-AMP Phosphodiesterases, http://linkedlifedata.com/resource/pubmed/chemical/5-nitro-2-(3-phenylpropylamino)benzo..., http://linkedlifedata.com/resource/pubmed/chemical/Acetylcholine, http://linkedlifedata.com/resource/pubmed/chemical/Cobalt, http://linkedlifedata.com/resource/pubmed/chemical/Cyclic Nucleotide..., http://linkedlifedata.com/resource/pubmed/chemical/Glyburide, http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles, http://linkedlifedata.com/resource/pubmed/chemical/Nitrobenzoates, http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Potassium, http://linkedlifedata.com/resource/pubmed/chemical/Potassium Channel Blockers, http://linkedlifedata.com/resource/pubmed/chemical/Pyridones, http://linkedlifedata.com/resource/pubmed/chemical/Sodium, http://linkedlifedata.com/resource/pubmed/chemical/olprinone
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
129
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1000-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:10696101-3',5'-Cyclic-AMP Phosphodiesterases, pubmed-meshheading:10696101-Acetylcholine, pubmed-meshheading:10696101-Animals, pubmed-meshheading:10696101-Cobalt, pubmed-meshheading:10696101-Coronary Vessels, pubmed-meshheading:10696101-Cyclic Nucleotide Phosphodiesterases, Type 3, pubmed-meshheading:10696101-Electrophysiology, pubmed-meshheading:10696101-Glyburide, pubmed-meshheading:10696101-Hypoglycemic Agents, pubmed-meshheading:10696101-Imidazoles, pubmed-meshheading:10696101-Isometric Contraction, pubmed-meshheading:10696101-Male, pubmed-meshheading:10696101-Membrane Potentials, pubmed-meshheading:10696101-Muscle, Smooth, Vascular, pubmed-meshheading:10696101-Nitrobenzoates, pubmed-meshheading:10696101-Phosphodiesterase Inhibitors, pubmed-meshheading:10696101-Potassium, pubmed-meshheading:10696101-Potassium Channel Blockers, pubmed-meshheading:10696101-Pyridones, pubmed-meshheading:10696101-Rabbits, pubmed-meshheading:10696101-Sodium, pubmed-meshheading:10696101-Vascular Resistance, pubmed-meshheading:10696101-Vasodilation
pubmed:year
2000
pubmed:articleTitle
Possible mechanisms underlying the vasodilatation induced by olprinone, a phosphodiesterase III inhibitor, in rabbit coronary artery.
pubmed:affiliation
Department of Pharmacology, Nagoya City University Medical School, Mizuho-Ku, Nagoya 467-8601, Japan.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't